Xenetic Biosciences, Inc.
XBIONasdaq
$2.78
↓ -1.0%Jul 17 close · end-of-day
Price
1Y↓ -23.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.4M
Enterprise Value
$6.4M
P/E
—
P/S
2.0
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$3.2M
Net Income (TTM)
-$2.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-75.0%
Net Margin
-70.0%
ROE
-32.1%
ROIC
-27.2%
Debt / Equity
—
Net Cash
—
Return 1Y
-24.6%
Company profile
Xenetic Biosciences, Inc. focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC.
- CEO
- Jeffrey F. Eisenberg
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- Massachusetts
- Website
- xeneticbio.com
Earnings
XBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$806,923.00↑ +36.0%
Diluted EPS-$0.20↓ -66.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $436,942.00 | $1.2M | $1.7M | $2.5M | $2.5M | $3.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.9M | -$5.7M | -$6.7M | -$4.5M | -$4.2M | -$2.8M |
| Net income | -$10.9M | -$5.6M | -$6.6M | -$4.1M | -$4.0M | -$2.7M |
| Diluted EPS | — | -$0.55 | -$4.61 | -$2.71 | -$2.57 | -$1.58 |
| Operating cash flow | -$4.3M | -$4.7M | -$4.6M | -$4.1M | -$2.8M | -$2.3M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -3189.8% | -495.1% | -393.6% | -177.8% | -168.2% | -95.2% |
| Net margin | -2493.1% | -486.4% | -383.9% | -162.8% | -158.4% | -90.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $726,404.00 | $614,243.00 | $648,820.00 | $593,261.00 | $589,897.00 | $1.0M | $766,296.00 | $806,923.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.3M | -$499,473.00 | -$1.1M | -$942,409.00 | -$724,412.00 | -$544,734.00 | -$623,027.00 | -$502,117.00 |
| Net income | -$1.3M | -$436,671.00 | -$1.1M | -$903,141.00 | -$688,703.00 | -$509,940.00 | -$579,076.00 | -$456,382.00 |
| Diluted EPS | -$0.83 | -$0.28 | -$0.68 | -$0.59 | -$0.45 | -$0.33 | -$0.21 | -$0.20 |
| Operating cash flow | -$525,104.00 | -$459,037.00 | -$673,992.00 | -$1.0M | -$383,830.00 | -$658,247.00 | -$242,682.00 | -$536,377.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -184.1% | -81.3% | -169.4% | -158.9% | -122.8% | -53.0% | -81.3% | -62.2% |
| Net margin | -175.4% | -71.1% | -162.5% | -152.2% | -116.7% | -49.7% | -75.6% | -56.6% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.